We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
-$341M
Cap. Flow %
-19.04%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Real Estate 0.39%
4 Financials 0.33%
5 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
126
DELISTED
Cidara Therapeutics
CDTX
$170K 0.01%
11,234
– –
CFRX
127
DELISTED
ContraFect Corporation
CFRX
$144K 0.01%
18,750
– –
CDAK
128
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$80K ﹤0.01%
200,000
– –
SNTI icon
129
Senti Biosciences Holdings
SNTI
$10.8M
$78K ﹤0.01%
5,556
-100,000
-95% -$2.44M
ADBE icon
130
Adobe
ADBE
$105B
– –
-1,300
Closed -$358K
ARGX icon
131
argenx
ARGX
$55.2B
– –
-150,000
Closed -$53M
ATXS
132
DELISTED
Astria Therapeutics
ATXS
– –
-33,333
Closed -$301K
AVTR icon
133
Avantor
AVTR
$9.82B
– –
-45,000
Closed -$882K
NERV icon
134
Minerva Neurosciences
NERV
$191M
– –
-250,000
Closed -$2.31M
SPRO icon
135
Spero Therapeutics
SPRO
$68.9M
– –
-500,000
Closed -$1M
THRD
136
DELISTED
Third Harmonic Bio
THRD
– –
-200,000
Closed -$3.79M
XBI icon
137
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-5,000,000
Closed -$397M
YI
138
111 Inc
YI
$31.3M
– –
-68,643
Closed -$1.84M
MRNS
139
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-157,000
Closed -$1.04M
SGEN
140
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,000
Closed -$13.7M
SGEN
141
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-350,000
Closed -$47.9M
AXLA
142
DELISTED
Axcella Health Inc. Common Stock
AXLA
– –
-28,500
Closed -$1.22M
ISEE
143
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-500,000
Closed -$8.97M
SGTX
144
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
– –
-21,231
Closed -$139K
CNCE
145
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-573,062
Closed -$3.84M
OMEG
146
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
– –
-750,000
Closed -$7.45M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group withdrew a net $341M in Q4 2022, closing 17 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, Artal Group opened a new position in Revolution Medicines worth $23.8M.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.